urothelial carcinoma
News/ News/ News/ Oncology/ R&D
End of the line for BMS, Nektar’s bempegaldesleukin/Opdivo alliance
Phil Taylor
Bristol-Myers Squibb, immuno-oncology, Nektar Therapeutics, Oncology, renal cell carcinoma, urothelial carcinoma
0 Comment
Scotland backs Bavencio for bladder cancer after NICE says no
Phil Taylor
Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma
0 Comment
NICE says no to Merck Serono’s Bavencio in bladder cancer
Phil Taylor
Bavencio, bladder cancer, checkpoint inhibitors, HEOR, immuno-oncology, Merck KGaA, Oncology, urothelial carcinoma
0 Comment
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance
Phil Taylor
Bavencio, bladder cancer, checkpoint inhibitors, immuno-oncology, Merck KGaA, Oncology, Pfizer, urothelial carcinoma
0 Comment
AZ stakes its claim in immunotherapy with bladder cancer filing
Andrew McConaghie
durvalumab, immunotherapy, urothelial carcinoma
0 Comment